BridgeMD
New treatment option for Distal Radius Fractures
Official title Clinical Study on the Healing of Distal Radius Fractures With Conservative Treatment Assisted by Fu's Subcutaneous Needling
ClinicalTrials.gov ID: NCT07054463
What this study is testing
- What it's testing
- The goal of this clinical trial is to evaluate the efficacy and safety of Fu's subcutaneous needling (FSN) therapy combined with rehabilitation exercises in promoting fracture healing after conservative treatment of distal radius fractures (DRFs) in adult patients (aged 18-85 years) with acute DRFs. The main questions it aims to answer are: Does FSN therapy accelerate radiographic union compared to Sham FSN therapy?
- Time commitment: about 8 weeks
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 85
You may be able to join if
- Participants meeting the diagnostic criteria for distal radius fractures as outlined in both the Evidence-Based Guidelines for Diagnosis and...
- Within 1 week post closed reduction and small splint immobilization treatment.
- Aged between 18 and 85 years (inclusive).
- Fracture caused by trauma.
- Acute fracture (≤2 weeks) or first-time fracture.
You likely can't join if
- Pathological, open, or nonacute fractures (\>2 weeks since injury).
- Patients with thrombocytopenia, bleeding tendency, or coagulation disorders (INR \>1.5 or platelet count \<50×10⁹/L).
- Cognitive impairment or psychiatric disorders affecting treatment compliance and follow-up.
- Local skin lesions, pregnancy, or lactation.
- History of syncope during Fu's subcutaneous needling therapy or intolerance to the procedure.
- Participation in other treatment clinical trials within the past 3 months.
See the full eligibility criteria
- Participants meeting the diagnostic criteria for distal radius fractures as outlined in both the Evidence-Based Guidelines for Diagnosis and Treatment of Adult Distal Radius Fractures (2024) (10) and the clinical...
- Within 1 week post closed reduction and small splint immobilization treatment.
- Aged between 18 and 85 years (inclusive).
- Fracture caused by trauma.
- Acute fracture (≤2 weeks) or first-time fracture.
- No prior history of receiving Fu's subcutaneous needling therapy.
- Signed informed consent form obtained.
- Pathological, open, or nonacute fractures (\>2 weeks since injury).
- Patients with thrombocytopenia, bleeding tendency, or coagulation disorders (INR \>1.5 or platelet count \<50×10⁹/L).
- Cognitive impairment or psychiatric disorders affecting treatment compliance and follow-up.
- Local skin lesions, pregnancy, or lactation.
- History of syncope during Fu's subcutaneous needling therapy or intolerance to the procedure.
- Participation in other treatment clinical trials within the past 3 months.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 8 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.